The BioCentury Show
By BioCentury
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BioCentury
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 61
Description
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
| Episode | Date |
|---|---|
|
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
|
May 15, 2026 |
|
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
|
May 01, 2026 |
|
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
|
Apr 17, 2026 |
|
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
|
Apr 03, 2026 |
|
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
|
Mar 20, 2026 |
|
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
|
Mar 06, 2026 |
|
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
|
Feb 18, 2026 |
|
Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs
|
Feb 06, 2026 |
|
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
|
Jan 23, 2026 |
|
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
|
Jan 09, 2026 |
|
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma
|
Dec 19, 2025 |
|
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw
|
Dec 05, 2025 |
|
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
|
Nov 27, 2025 |
|
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science
|
Nov 14, 2025 |
|
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook
|
Oct 31, 2025 |
|
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem
|
Oct 16, 2025 |
|
Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape
|
Oct 03, 2025 |
|
Ep. 93 – BIO’s Fritz Bittenbender on Trump 2.0, MFN Threats & Pharma’s Concessions
|
Sep 18, 2025 |
|
Ep. 92 - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
|
Sep 06, 2025 |
|
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech
|
Aug 22, 2025 |
|
Popular Episode - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
|
Aug 13, 2025 |
|
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want
|
Jul 24, 2025 |
|
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett
|
Jul 10, 2025 |
|
Ep. 88 – From Satiety to Muscle: Zealand CEO Steensberg on Amylin’s Edge in Obesity
|
Jun 27, 2025 |
|
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
|
Jun 13, 2025 |
|
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
|
Jun 04, 2025 |
|
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
|
May 29, 2025 |
|
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
|
May 21, 2025 |
|
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
|
May 02, 2025 |
|
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
|
Apr 17, 2025 |
|
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
|
Apr 04, 2025 |
|
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
|
Mar 20, 2025 |
|
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
|
Mar 08, 2025 |
|
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
|
Feb 20, 2025 |
|
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
|
Feb 07, 2025 |
|
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
|
Jan 24, 2025 |
|
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
|
Jan 13, 2025 |
|
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
|
Jan 10, 2025 |
|
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
|
Dec 13, 2024 |
|
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
|
Nov 14, 2024 |
|
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
|
Oct 31, 2024 |
|
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
|
Oct 18, 2024 |
|
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
|
Oct 04, 2024 |
|
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
|
Sep 19, 2024 |
|
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
|
Sep 05, 2024 |
|
Popular Episode - Bob Nelsen on AI, China and the IRA
|
Aug 22, 2024 |
|
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
|
Aug 08, 2024 |
|
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
|
Jul 25, 2024 |
|
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
|
Jul 11, 2024 |
|
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
|
Jun 27, 2024 |
|
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
|
Jun 13, 2024 |
|
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
|
May 31, 2024 |
|
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech
|
May 30, 2024 |
|
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
|
May 16, 2024 |
|
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D
|
May 02, 2024 |
|
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
|
May 02, 2024 |
|
Ep. 52 - Khoo Shih on Scaling Singapore Biotech
|
Apr 17, 2024 |
|
Ep. 53 - Bob Nelsen on AI, China and the IRA
|
Apr 17, 2024 |
|
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm
|
Apr 17, 2024 |
|
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening
|
Apr 17, 2024 |
|
Ep. 56 - BIO’s John Crowley on the Biosecure Act
|
Apr 17, 2024 |